Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: 12 recruiting locations
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06051695
Phase1, Phase2, Recruiting
Active & Responsive
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
for
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer,